Jens Juul Holst (born 1 August 1945) is a Danish physician and physiologist. He is known for discovering and describing the hormone glucagon-like peptide-1 (GLP-1), a hormone in the gut that plays an important role in the onset and development of Type 2 diabetes.[1]
In 2020, he was awarded the Warren Alpert Foundation Prize along Daniel J. Drucker and Joel F. Habener.[2]
In 2021, he was awarded the Canada Gairdner International Award along Daniel J. Drucker, Joel F. Habener, and Mary-Claire King.[3] He was also awarded the Banting Medal by the American Diabetes Association (ADA).[4]
In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, and Svetlana Mojsov.[5] and also in 2024 he received the Tang Prize in the category of "Biopharmaceutical Science".[6]
References
- ^ Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
- ^ Prize Recipients | Warren Alpert Foundation Prize
- ^ "2021 Canada Gairdner Awards Recognize World-Renowned Scientists For Transformative Contributions To Research Impacting Human Health". 7 April 2021. Retrieved 13 December 2021.
- ^ "Exceptional Leaders in Diabetes Research, Prevention and Treatment to be Recognized at ADA's 81st Scientific Sessions" (PDF; 269 kB). diabetes.org. American Diabetes Association. 2021-03-08.
- ^ "Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, Jens Juul Holst, and Svetlana Mojsov, Princess of Asturias Award for Technical and Scientific Research 2024". Princess of Asturias Foundation. 5 June 2024.
- ^ Tang Prize 2024
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
Recent Comments